This Granules’ CSR initiative aims to empower students and researchers with access to cutting-edge facilities and resources, fostering innovation in eco-friendly solutions for learning pharmaceutical manufacturing.
Speaking at the inauguration, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited, said, “At Granules, we believe that innovation and sustainability go hand in hand. Guided by our purpose of Healing Lives Responsibly through Pioneering Green Science, this initiative reflects our commitment to shaping a healthier, more sustainable future, not only for our stakeholders, but also for the communities and ecosystems that sustain us.”
Prof. Dulal Panda, Director, NIPER S.A.S Nagar, added, "This collaboration brings academia and industry together to solve real-world challenges. By focusing on green cand sustainable practices, we can deliver solutions that benefit both the environment and patients worldwide."
As per the release, the Centre, under the supervision of Dr. Arvind.K Bansal, Professor Department of Pharmaceutics, Lead and Academic Supervisor of the Centre will harness NIPER’s academic and research strengths alongside Granules India’s industrial expertise to develop scalable, eco-friendly solutions for the pharmaceutical sector.
The collaboration will focus on interface between API and formulation manufacturing, reducing the carbon footprint in formulation production, creating intellectual property in sustainable technologies, training next-generation scientists, and setting new industry benchmarks in sustainable manufacturing.
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. Granules is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.